

DEPARTMENT OF HEALTH AND HUMAN SERVICES



Stacie Weeks, JD MPH Administrator

DIVISION OF HEALTH CARE FINANCING AND POLICY Helping people. It's who we are and what we do.

Silver State Scripts Board Meeting Minutes

Date of Meeting: Thursday, December 14, 2023, at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and

Policy (DHCFP), Silver State Scripts Board.

Agenda Item	Record			Notes
1. Closed Executive Session				
a. Call to Order and Roll Call	Chairperson Mark Decerbo called the r December 14, 2023. Chairperson Decerbo took the roll. Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair Joseph Adashek, MD Mark Crumby, Pharm. D. Elizabeth Gonzalez, Pharm.D. Sapandeep Khurana, MD Isabella Niezborala, Pharm.D. Leana Ramirez, Pharm.D. Aditi Singh, MD	Present	Absent	DHCFP Staff Present were as follows: Lither, Gabriel, Senior Deputy Attorney General (SDAG) Duncan, Keiko, PharmD, Medicaid Pharmacy Director Clemons, Roshanda, MD, Medicaid Medical Director Flowers, Ellen, Program Officer I (PO) NMAP Staff Present were as follows:
				Johnson, Tory, Health Program Manager II

			Cowan, Sarah, Health Program Specialist I
			Magellan Rx Staff Present were as follows: Mishra, Raj, Pharm.D., Clinical Account Manager Kim, James, Pharm.D., Dir.
			 Clinical Account Services Martinez, Chris, Sr. Business Analyst Perez, Melissa, Sr. Business Analyst
b.	Financial Review of Drug Classes with Proposed Changes	Chairman Decerbo directed Dr. Raj Mishra to proceed with the Financial Review of Drug classes with proposed changes up for review. Dr. Mishra reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside this closed session of the Silver States Scripts Board meeting. Dr. Mishra presented the financial review of the established drug classes being reviewed due to the release of new drugs, noting the products with proposed changes in PDL status. • Atypical Antipsychotics – Long Acting Injectable • Substance Abuse Agents Dr. Mishra presented the financial review of the established drug classes being reviewed due to the release of new generics, noting the products	
		with proposed changes in PDL status. • ADHD Agents Dr. Mishra presented the financial review of the established drug classes with proposed changes, noting the products with proposed changes in	

	PDL status. • Antiglaucoma Agents • Inhaled Glucocorticoids • Long-Acting Insulins			
2. Open Public Meeting	•			
a. Call to Order and Roll Call	Chairman Decerbo called the meeting of 14, 2023. A quorum was present. Chairperson Decerbo took the roll. Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair Joseph Adashek, MD Mark Crumby, Pharm. D. Elizabeth Gonzalez, Pharm.D. Sapandeep Khurana, MD Isabella Niezborala, Pharm.D. Leana Ramirez, Pharm.D. Aditi Singh, MD	Present S S S C D S C D D C D D D D D D D D D	Absent □ □ □ □ □ □ □ □ □ □ □ □ □ □	 DHCFP Staff Present were as follows: Lither, Gabriel, Senior Deputy Attorney General (SDAG) Duncan, Keiko, PharmD, Medicaid Pharmacy Director Clemons, Roshanda, MD, Medicaid Medical Director Flowers, Ellen, Program Officer I (PO) NMAP Staff Present were as follows: Johnson, Tory, Health Program Manager II Cowan, Sarah, Health Program Specialist I Magellan Rx Staff Present were as follows: Mishra, Raj, Pharm.D., Clinical Account Manager Kim, James, Pharm.D., Dir. Clinical Account Services Martinez, Chris, Sr.
				Business Analyst

			Perez, Melissa, Sr. Business Analyst
b.	Approval for previous Meeting Minutes from September 28, 2023, and	By unanimous consent, the minutes were approved.	The public attendee list is included as Attachment A. Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list's accuracy is not assured
C.	October 05, 2023. Public Comments	Telephonic and web comment was called for, and the phone lines were opened.	
		No public comments were provided.	
d.	Status Update by DHCFP	Medicaid Pharmacy Director, Dr. Keiko Duncan, provided an announcement.	
		 I want to just introduce myself, I am Dr. Keiko Duncan. I am the new Medicaid Pharmacy Director for Nevada. I am a pharmacist myself and I am new to Nevada, so very excited to be here. And beyond that, we do have some additional positions that we are still filling within my Pharmacy Services and DME Unit. So I am looking forward to providing more of an update during our next meeting. 	
e.	Status Update by NMAP	Health Program Specialist, Sarah Cowan, provided an announcement.	
		Sunlenca is now available to NMAP clients in Southern Nevada who are uninsured or who's insurance does not cover Sunlenca through community outreach Medical Center.	

3. Clinica	l Presentations					
and Aty	r Possible Action: Discussion d possible adoption of ypical Antipsychotics – Long ting Injectable.					
i.	Public comment	Telephonic and web comment was opened.	called f	or, and	the phone lines were	
		No public comment was provided.				
ii.	Drug class review presentation by MagellanRx	presented the availability within the	Dr. Mishra discussed Rykindo, the new product within this drug class. He presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.			
		Dr. Mishra recommended the Board therapeutically equivalent.	d consic	ler the	class clinically and	
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in	Chair Decerbo moved to accept the equivalent presented by Magellan, the motion. A vote was taken, and the results w	and Vic	e Chair	Kate Ward seconded	
	class.	attendance (in favor, against, and a				
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	\boxtimes			
		Kate Ward, Pharm.D., Vice Chair	\boxtimes			
		 Joseph Adashek, MD 				
		 Mark Crumby, Pharm.D. 	\boxtimes			
		• Elizabeth Gonzalez, Pharm.D.	\boxtimes			
		 Sapandeep Khurana, MD 	\boxtimes			

	• Isabella Niezborala, Pharm.D.	\boxtimes			
	 Leana Ramirez, Pharm.D. 			\boxtimes	
	 Aditi Singh, MD 			\boxtimes	
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended adding R	ykindo (on the	PDL as non-prefer	red.
v. Discussion by Board and	Vice Chair Ward moved to approve		•		nted
action by Board for approval of drugs for	by Magellan and Board Member Go	nzalez	second	ed the motion.	
inclusion on the PDL.	A vote was taken, and the results w	ere as f	ollows	from members in	
	attendance (in favor, against, and a	bstenti	ons wh	ere applicable):	
		Yes	No	Abst.	
	 Mark Decerbo, Pharm.D., Chair 	\boxtimes			
	 Kate Ward, Pharm.D., Vice Chair 	\boxtimes			
	 Joseph Adashek, MD 			\boxtimes	
	 Mark Crumby, Pharm.D. 	\boxtimes			
	• Elizabeth Gonzalez, Pharm.D.	\boxtimes			
	 Sapandeep Khurana, MD 	\boxtimes			
	• Isabella Niezborala, Pharm.D.	\boxtimes			
	 Leana Ramirez, Pharm.D. 			\boxtimes	
	Aditi Singh, MD			\boxtimes	
B. For Possible Action: Discussion and possible adoption of Substance Abuse Agents.					
i. <u>Public comment</u>	Telephonic and web comment was opened.	vere			
	Public comment was provided by Ko	enneth	Berry,	Medical Science	

	Drug class review presentation by MagellanRx	Dr. Mishra discussed Brixadi, the ne presented the availability within the mechanism of action, and efficacy so Dr. Mishra recommended the Board therapeutically equivalent.	e drug c tudies.	lass an	d noted the indication,	
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chair Decerbo moved to accept the equivalent presented by Magellan a seconded the motion. A vote was taken, and the results was attendance (in favor, against, and a	and Boa ere as fo	rd Mer	mber Gonzalez from members in	
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	\boxtimes			
		Kate Ward, Pharm.D., Vice Chair	\boxtimes			
		 Joseph Adashek, MD 			\boxtimes	
		Mark Crumby, Pharm.D.	\boxtimes			
		• Elizabeth Gonzalez, Pharm.D.	\boxtimes			
		Sapandeep Khurana, MD	\boxtimes			
		• Isabella Niezborala, Pharm.D.	\boxtimes			
		• Leana Ramirez, Pharm.D.			\boxtimes	
		 Aditi Singh, MD 			\boxtimes	
iv.	Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended adding Bi	rixadi to	the PI	DL as preferred.	
v.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Chair Decerbo moved to approve the Magellan and Board Member Gonza A vote was taken, and the results we	alez sec	onded	the motion.	

	attendance (in favor against and a					
	attendance (in lavor, against, and a	attendance (in favor, against, and abstentions where applicable):				
		Yes	No	Abst.		
	Mark Decerbo, Pharm.D., Chair	\boxtimes				
	Kate Ward, Pharm.D., Vice Chair	\boxtimes				
	Joseph Adashek, MD			\boxtimes		
	Mark Crumby, Pharm.D.	\boxtimes				
	Elizabeth Gonzalez, Pharm.D.	\boxtimes				
	Sapandeep Khurana, MD	\boxtimes				
	• Isabella Niezborala, Pharm.D.	\boxtimes				
	 Leana Ramirez, Pharm.D. 			\boxtimes		
	Aditi Singh, MD			\boxtimes		
C. For Possible Action: Discussion and possible adoption of ADHD Agents.						
i. <u>Public Comment</u>	Telephonic and web comment was opened. No public comment was provided.	called fo	or, and	the phone lines were		
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board therapeutically equivalent.	d consid	ler the	class clinically and		
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chair Decerbo moved to accept the equivalent presented by Magellan a seconded the motion. A vote was taken, and the results we attendance (in favor, against, and a	and Boa ere as fo bstentio	rd Mer ollows ons wh	mber Gonzalez from members in ere applicable):		
		Yes	No	Abst.		

			Mark Decerbo, Pharm.D., Chair	\boxtimes					
			Kate Ward, Pharm.D., Vice Chair	\boxtimes					
			 Joseph Adashek, MD 			\boxtimes			
			 Mark Crumby, Pharm.D. 	\boxtimes					
			• Elizabeth Gonzalez, Pharm.D.	\boxtimes					
			 Sapandeep Khurana, MD 	\boxtimes					
			• Isabella Niezborala, Pharm.D.	\boxtimes					
			 Leana Ramirez, Pharm.D. 			\boxtimes			
			Aditi Singh, MD			\boxtimes			
	IV.	Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended adding lis Vyvanse®) and methylphenidate pa preferred.						
	V.	Comment by the Board	Board Member Sapandeep Khurana process does Magellan has due to s preferred medication.	•					
	vi.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Vice Chair Ward moved to approve by Magellan and Board Member Ma A vote was taken, and the results we attendance (in favor, against, and a	ark Crur ere as fo	nby se	conded t	he motion.		
				Yes	No	Abst.			
			Mark Decerbo, Pharm.D., Chair	X					
			Kate Ward, Pharm.D., Vice Chair	\boxtimes					
			Joseph Adashek, MD			⊠			
			Mark Crumby, Pharm.D.	\boxtimes					
			• Elizabeth Gonzalez, Pharm.D.	\boxtimes					
			Sapandeep Khurana, MD		\boxtimes				
			 Isabella Niezborala, Pharm.D. 	\boxtimes					
ı	l e e e e e e e e e e e e e e e e e e e			بنا				1	

	 Leana Ramirez, Pharm.D. 			\boxtimes	
	 Aditi Singh, MD 			\boxtimes	
 D. For Possible Action: Discussion and possible adoption of Antiglaucoma Agents. 					
i. <u>Public Comment</u>	Telephonic and web comment was opened. No public comment was provided.	called fo	r, and	the phone lines were	
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board therapeutically equivalent.	d consid	er the	class clinically and	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chair Decerbo moved to accept the equivalent presented by Magellan a seconded the motion. A vote was taken, and the results w attendance (in favor, against, and a	and Boa ere as fo	rd Mer ollows	mber Gonzalez from members in	
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	\boxtimes			
	Kate Ward, Pharm.D., Vice Chair	\boxtimes			
	 Joseph Adashek, MD 			\boxtimes	
	 Mark Crumby, Pharm.D. 	\boxtimes			
	• Elizabeth Gonzalez, Pharm.D.	\boxtimes			
	 Sapandeep Khurana, MD 	\boxtimes			
	• Isabella Niezborala, Pharm.D.	\boxtimes			
	 Leana Ramirez, Pharm.D. 			\boxtimes	
	 Aditi Singh, MD 			\boxtimes	

	Presentation of recommendations for PDL inclusion by MagellanRx Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Dr. Mishra recommended adding lyuzeh ™, Phospholine lodide® and tafluprost (generic for Zioptan®) on the PDL as non-preferred. Chair Decerbo moved to approve the proposed changes as presented by Magellan and Board Member Gonzalez seconded the motion. A vote was taken, and the results were as follows from members in				
		attendance (in favor, against, and a	bstentic	ns wh	ere applicable):	
			.,			
		AA J Danielo Blanco D Claric	Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair Mark Decerbo, Pharm.D., Chair Mark Decerbo, Pharm.D., Chair	\boxtimes			
		Kate Ward, Pharm.D., Vice Chair Adaphak Adaphak AAD	\boxtimes			
		Joseph Adashek, MD Mark Grupehy, Bharra B				
		Mark Crumby, Pharm.D. Size bath Countries Blooms B.	\boxtimes			
		Elizabeth Gonzalez, Pharm.D.	\boxtimes			
		Sapandeep Khurana, MD	\boxtimes			
		Isabella Niezborala, Pharm.D.	\boxtimes			
		Leana Ramirez, Pharm.D.			\boxtimes	
	D 111 A 11 D1 1	Aditi Singh, MD			X	
and	Possible Action: Discussion dipossible adoption of laled Glucocorticoids.					
i.	<u>Public Comment</u>	Telephonic and web comment was opened.	called fo	or, and	the phone lines were	
		No public comment was provided.				
ii.	Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board therapeutically equivalent.	l consid	er the	class clinically and	

iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Chair Decerbo moved to accept the equivalent presented by Magellan a seconded the motion. A vote was taken, and the results we attendance (in favor, against, and a	ind Boa ere as fo	rd Mer	nber Gonzalez from members in	
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	\boxtimes			
		Kate Ward, Pharm.D., Vice Chair	\boxtimes			
		Joseph Adashek, MD			\boxtimes	
		Mark Crumby, Pharm.D.	\boxtimes			
		• Elizabeth Gonzalez, Pharm.D.	\boxtimes			
		Sapandeep Khurana, MD	\boxtimes			
		• Isabella Niezborala, Pharm.D.	\boxtimes			
		 Leana Ramirez, Pharm.D. 			\boxtimes	
		Aditi Singh, MD			\boxtimes	
iv.	Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended moving A preferred.				
		Dr. Mishra also recommended addi (generic for Flovent HFA®) and flution Flovent Diskus®) to the PDL as prefe	casone _l		· · ·	
V.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Chair Decerbo moved to approve the Magellan and Board Member Gonza			• ,	
		A vote was taken, and the results we attendance (in favor, against, and a			ere applicable):	
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	\boxtimes			

	Kate Ward, Pharm.D., Vice Chair	\boxtimes				
	 Joseph Adashek, MD 			\boxtimes		
	 Mark Crumby, Pharm.D. 	\boxtimes				
	• Elizabeth Gonzalez, Pharm.D.	\boxtimes				
	Sapandeep Khurana, MD	\boxtimes				
	• Isabella Niezborala, Pharm.D.	\boxtimes				
	 Leana Ramirez, Pharm.D. 			\boxtimes		
	Aditi Singh, MD			\boxtimes		
F. For Possible Action: Discussion and possible adoption of Long-Acting Insulins.						
i. <u>Public Comment</u>	Telephonic and web comment was opened. No public comment was provided.					
	ivo public comment was provided.					
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board therapeutically equivalent.					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in	Chair Decerbo moved to accept the equivalent presented by Magellan a seconded the motion. A vote was taken, and the results w	and Boa	ırd Meı	mber Go	nzalez	
class.	attendance (in favor, against, and a					
		Yes	No	Abst.		
	Mark Decerbo, Pharm.D., Chair	\boxtimes				
	Kate Ward, Pharm.D., Vice Chair	\boxtimes				
	 Joseph Adashek, MD 			\boxtimes		
	 Mark Crumby, Pharm.D. 	\boxtimes				

	Elizabeth Gonzalez, Pharm.D.	\boxtimes			
	Sapandeep Khurana, MD	\boxtimes			
	 Isabella Niezborala, Pharm.D. 	\boxtimes			
	 Leana Ramirez, Pharm.D. 			\boxtimes	
	Aditi Singh, MD			\boxtimes	
		1: 1		VEC11	
iv. Presentation of recommendations for PDL	Dr. Mishra recommended adding in	isulin gla	argine	YFGN an	id Rezvogiar®
inclusion by MagellanRx	as non-preferred on the PDL.				
inclusion by Magenanix					
v. Discussion by Board and	Board Member Gonzalez moved to	approv	e the p	proposed	d changes as
action by Board for	presented by Magellan and Chair D	ecerbo :	second	led the r	notion.
approval of drugs for				_	
inclusion on the PDL.	A vote was taken, and the results w				
	attendance (in favor, against, and a	bstentic	ons wn	ere appi	icable):
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	×			
	Kate Ward, Pharm.D., Vice Chair	\boxtimes			
	Joseph Adashek, MD			\boxtimes	
	Mark Crumby, Pharm.D.	\boxtimes			
	Elizabeth Gonzalez, Pharm.D.	\boxtimes			
	Sapandeep Khurana, MD	\boxtimes			
	Isabella Niezborala, Pharm.D.	\boxtimes			
	Leana Ramirez, Pharm.D.			\boxtimes	
	Aditi Singh, MD			\boxtimes	
G. MagellanRx Reports	MRx Pipeline				
	CARDIOLOGY				
	NEUROLOGY DESCRIPATION				
	 RESPIRATORY 				

	MUSCULOSKELETAL	
	METABOLIC	
	RECENT FDA APPROVALS	
H. Closing Discussion		
i. Public comments on any	Public comments were provided by Valerie Ing, Pharmacist with	
subject	Medical Affairs at Leo Pharma.	
	Public comments were provided by Leah Case on behalf of the	
	Nevada Psychiatric Association.	
ii. Date and location of the	Date: March 21, 2024	
next meeting.	Location: Courtyard by Marriott Las Vegas Convention Center	
	3275 Paradise Road, Las Vegas, NV, 89109	
iii. Adjournment	Chairman Decerbo adjourned the meeting at 2:43 PM.	

Attachment A – Members of the Public in Attendance

Elisa Ashton	Krystal Riccio	Deron Grothe	Michael Zarob	Elinor Cruz	Jason Douglas
Ryan Bitton	Lea Case	Dominic Gaon	Nicholas Boyer	Georgette Dzwilewski	Jason Crecco
Nick Casale	Luke Lim	Garth Wright	Rogie Arellano	Deron Grothe	
Jeana Colabianchi	Mandeep Sohal	John Landis	Valerie D Ng	Karen On	
Marissa Connor	Mark Duerre	Kenneth Berry	Eric Perry	Jonathan Delgato	

Attachment B – Submitted Written Comment

None